Understanding More Sensitive Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD

Posted on: May 31, 2023

Play Episode

Also available on

Spotify

Apple Podcasts

Youtube

Description

CALL 347-637-2631 TO JOIN BY PHONE AND ASK QUESTIONS

A wave of blood-based tests are being developed for myeloma care, and for good reason. Patients love the idea of replacing the painful bone marrow biopsy with a blood-based test, especially if it is equally effective. In addition to being less time consuming and painful, blood-based testing could be performed more regularly to provide more information to patients and their doctors.

The types of test vary. They include mass spectometry testing, blood-based MRD testing and circulating tumor cell testing. Many of these tools are still only used in research, but they are getting closer to being used in the myeloma clinic. Each of the tests have unique ways of providing a less invasive way of testing for myeloma at diagnosis and after treatment.

Ola Landgren, MD, PhD of the University of Miami Sylvester Cancer Center joins HealthTree Podcast for Multiple Myeloma to review the different types of tests, how they function, what they measure, pros and cons of each and how they are and could be used in regular myeloma practice.

As we continue to see these tests advance, it's a great idea to start becoming more familiar with the test types, test names and reasons for their use.

Thanks to our episode sponsor

User uploaded media

We appreciate your donations to support the HealthTree Podcast for Multiple Myeloma.

DONATE

Overview

New blood-based tests are in development and coming closer to the myeloma clinic. Patients love the idea of reducing or eliminating the traditional bone marrow biopsy.

In this podcast, Dr. Ola Landgren shares multiple types of blood-based tests that help detect myeloma and measure minimal residual disease. Tests reviewed include mass spectrometry tests, MRD tests, flow cytometry tests and circulating tumor cell tests.

On this episode

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Transcript

Understanding More Sensitive Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD

Related Content